This brand name is authorized in Hong Kong, Japan, United States
The drug LINZESS contains one active pharmaceutical ingredient (API):
|
1
Linaclotide
UNII N0TXR0XR5X - LINACLOTIDE
|
|
Linaclotide is a Guanylate Cyclase-C receptor agonist (GCCA) with visceral analgesic and secretory activities. Through its action at GC-C, linaclotide has been shown to reduce visceral pain and increase GI transit in animal models and increase colonic transit in humans. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| LINZESS Capsule, gelatin coated | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: HK | Department of Health Drug Office | Identifier(s): 64139 |
| Country: JP | 医薬品医療機器総合機構 | Identifier(s): 2399017F1020 |
| Country: US | FDA, National Drug Code | Identifier(s): 0456-1201, 0456-1202, 0456-1203 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
